Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.41 |
| ▸ | CES1 | P23141 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.37 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.37 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | NSD1 | Q96L73 | 1/20 | 0.37 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10351386 | 0.86 | TSHR (0.33) | MAOACES1PLAUTSHRMAOB | |
| SCHEMBL3590143 | 0.86 | TSHR (0.40) | MAOACES1PLAUTSHRMAOB | |
| SCHEMBL10846631 | 0.74 | PLAU (0.41) | MAOACES1PLAUTSHRMAOB | |
| SCHEMBL6508302 | 0.74 | PLAU (0.41) | MAOACES1PLAUTSHRMAOB | |
| SCHEMBL14362040 | 0.74 | PLAU (0.37) | MAOACES1PLAUTSHRMAOB | |
| SCHEMBL61808 | 0.68 | MAOA (0.44) | MAOACES1TSHRMAOBBCHE | |
| SCHEMBL242542 | 0.67 | — | — | |
| SCHEMBL29517242 | 0.67 | — | — | |
| SCHEMBL50865 | 0.67 | MAOA (0.50) | MAOACES1MAOBBCHEACHE | |
| SCHEMBL30252635 | 0.67 | MAOA (0.50) | MAOACES1MAOBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119923263-A | Pharmaceutical composition containing isoquinolinones and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024127413-A1 | SOLID STATE FORMS OF ENSIFENTRINE | CIPLA LIMITED (IN) | 2024-06-20 | — | — | WO | claimed |
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2023-08-03 | — | — | US | claimed |
| CN-114280200-B | Method for simultaneously detecting three component contents of praziquantel, clofenacin and milbexime | 上海汉维生物医药科技有限公司 | 2023-07-07 | — | — | CN | claimed |
| EP-4186507-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2023-05-31 | — | — | EP | claimed |
| CN-114280200-A | Method for simultaneously detecting content of three components of praziquantel, clofenacin and milbemycin oxime | 上海汉维生物医药科技有限公司 | 2022-04-05 | — | — | CN | claimed |
| EP-3710004-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | Galapagos NV (BE) | 2020-09-23 | — | — | EP | claimed |
| EP-3231444-B1 | NEW TREATMENT | VERONA PHARMA PLC (GB) | 2019-12-18 | — | — | EP | claimed |
| EP-1165558-B1 | DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE | VERNALIS LTD (GB) | 2003-09-24 | — | — | EP | claimed |
| WO-2000078149-A1 | ANTHELMINTIC COMPOSITIONS | BAYER AKTIENGESELLSCHAFT (DE) | 2000-12-28 | — | — | WO | claimed |
| US-5728705-A | Method of inducing vasorelaxation to treat pulmonary hypertension | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 1998-03-17 | — | — | US | claimed |
| EP-0242190-B1 | SILVER HALIDE PHOTOGRAPHIC MATERIALS HAVING RHODIUM CYANIDE DOPANTS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-04-01 | — | — | EP | claimed |
| EP-0242190-A2 | Silver halide photographic materials having rhodium cyanide dopants | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1987-10-21 | — | — | EP | claimed |
| EP-4609864-A1 | PHARMACEUTICAL COMPOSITION CONTAINING ISOQUINOLINONE COMPOUND, AND PREPARATION METHOD THEREFOR | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-09-03 | — | — | EP | disclosed |
| WO-2025124460-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR | 石家庄以岭药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2025124459-A1 | TRICYCLIC FUSED HETEROCYCLIC PDE3/4 DUAL INHIBITOR, AND PREPARATION AND USE THEREFOR | 石家庄以岭药业股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-4269927-A | DOPED WITH CADMIUM, LEAD, COPPER, OR ZINC OR MIXTURES; HIGH SPEED COLOR FILMS; LOW CONCENTRATION OF SILVER IODIDE | EASTMAN KODAK COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
| US-4269914-A | INCLUDING A LAYER TO RECEIVE AND IMMOBILIZE A DIFFUSIBLE DESENSITIZER ABLE TO EFFECT THE SENSITIVITY OF A SILVER HALIDE EMULSION TO ELECTROMAGNETIC RADIATION AND A BARRIER LAYER | EASTMAN KODAK COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
| EP-0017148-A1 | Internally doped high chloride silver halide emulsions, processes for their preparation and photographic elements | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1980-10-15 | — | — | EP | disclosed |
| EP-0010759-A2 | Pyrimido (6,1-a) isoquinolin-4-ones, process for their preparation and their application in medicaments; intermediates and their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241068-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF FIBROTIC DISEASES | GPR84, GPR65, GPR88 | MAOA 2315/4885CES1 953/4885PLAU 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.